Luljeta Abdullahu¹*, Vjollca Dedushaj-Fazliu², Violeta Grajçevci-Uka³, Neshet Rizvanolli⁴, Idriz Geqari⁵, Rame Miftari⁵, Ismet Bajrami⁵, Fakir Spahiu⁵, Aferdita Bajqinca⁵, Armend Jashari⁵, Ylli Kaçiu⁵, Aferdita Xhelili⁵ and Fitore Murati-Abdullahu⁶

¹Department of Nuclear Medicine, University Clinical Center of Kosova, Republic of Kosovo
²Clinic of Endocrinology, University Clinical Center of Kosovo, Republic of Kosovo
³Clinic of Pediatric-Hemato-oncology Department, University Clinical Center of Kosovo, Republic of Kosovo
⁴MD of Interne Medicine and Master of Nuclear Medicine Et Private Heal Care, Republic of Kosovo
⁵Department of Nuclear Medicine, University Clinical Center of Kosovo, Republic of Kosovo
⁶Department of Physiotherapeutic, University Clinical Center of Kosovo, Republic of Kosovo

*Corresponding Author: Luljeta Abdullahu, Department of Nuclear Medicine, University Clinical Center of Kosovo, Republic of Kosovo.

Received: December 08, 2022; Published: December 28, 2022

Abstract

The aim of this study is to evaluated the outcome of 131I treatment in these to ariants of hyperthyreodism, respectively, to asses the incidence of hypothyroidism in these group of patients compared to group of patients with diffusely enlarged thyroid.

Material and Methods: We observed 226 patients treated with 131I during the five year period, from 2002 to 2007, 174(76.9%) with Graves's disease and diffuse toxic goiter. 25(11%) with multi nodular and 27(11.95%) with toxic nodule.

There were 42(20.80%) males and 184(81.24%) female patients, aged 22 to 70 year.

The treatment dose of 131-I was based on size of the nodule or thyroid gland, respectively, and radioiodine uptake.

Patients are followed for three to five years after they received J-131.

Results: The incidence of hypothyroidism was greater in Graves' disease than in multi nodular toxic and toxic nodular (Toxic Adenoma).

Most of patients ( 96%) with the solitary toxic nodule remained euthyroid up to five years after treated with 131-I.

Keywords. 131-I; Graves' Disease; Multi Nodular Toxic Goiter and Toxic Adenoma

References

1. Freitas JE. “Therapeutic options in the management of toxic and nontoxic nodular goiter”. Seminars in Nuclear Medicine 30 (2000): 88-97.
2. Weetman AP. “Graves’ disease”. New England Journal of Medicine 343 (2000): 1236-1248.
3. Cooper DS. “Hyperthyroidism”. Lancet 362 (2003): 459-468.
4. Philip JR., et al. “Treatment of thyrotoxicosis with ionizing radiation”. Lancet 2 (1968): 1307.
5. Torring O., et al. “Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine -- A prospective, randomized study”. The Journal of Clinical Endocrinology and Metabolism 81 (1996): 2986-2993.
6. Vitti P., et al. “Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment”. Thyroid 7 (1997): 369.
7. Scholz GH., et al. “Is there a place for thyroidectomy in older patients with thyrotoxic storm and cardiorespiratory failure?” Thyroid 13 (2003): 933.
8. Franklyn JA. “The management of hyperthyroidism”. New England Journal of Medicine 330 (1994): 1731-1738.
9. Solomon B., et al. “Current trends in the management of Graves' disease”. The Journal of Clinical Endocrinology and Metabolism 70 (1990): 1518-1524.
10. Chapman EM. “History of the discovery and early use of radioactive iodine”. Journal of the American Medical Association 250 (1983): 2042-2044.
11. Chapman EM and Maloof F. “The use of radioactive iodine in the diagnosis and treatment of hyperthyroidism: Ten years' experience”. Medicine 34 (1955): 261.
12. Russo D., et al. “Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas”. The Journal of Clinical Endocrinology and Metabolism 81 (1996): 1548.
13. Tonacchera M., et al. “Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma”. The Journal of Clinical Endocrinology and Metabolism 83 (1998): 492.
14. Dietlein M., et al. “Guideline for radioiodine therapy for benign thyroid diseases (version 4)”. Nuklearmedizin 46 (2007): 220.
15. Rivkees SA and Dinauer C. “An optimal treatment for pediatric Graves' disease is radioiodine”. The Journal of Clinical Endocrinology and Metabolism3 (2007): 797-800.
16. Jarløv VAE., et al. “Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile?” Clinical Endocrinology 43l (1995): 325-329.
17. Leslie WD., et al. “A randomized comparison of radioiodine doses in Graves’ hyperthyroidism”. Journal of Clinical Endocrinology and Metabolism 88 (2003): 978-983.
18. Catargi B., et al. “Optimized radioiodine therapy of Graves’ disease: analysis of the delivered dose and of other possible factors affecting outcome”. European Journal of Endocrinology 141 (1999): 117-121.
19. Alexander EK and Larsen PR. “High dose of 131I therapy for the treatment of hyperthyroidism caused by Graves’ disease”. Journal of Clinical Endocrinology and Metabolism 87 (2002): 1073-1077.

Citation

Citation: Luljeta Abdullahu., et al. “Incidence of Hypothyroidism in Patients with Diffuse and Toxic Nodular Goiter Treated with 131J”.Acta Scientific Medical Sciences 7.1 (2023): 83-85b.

Copyright

Copyright: © 2022 Luljeta Abdullahu., et al.. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.